Welcome to our dedicated page for Regentis Biomaterials SEC filings (Ticker: RGNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Regentis Biomaterials Ltd. (RGNT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 6-K and registration materials related to its NYSE American listing. As a foreign private issuer, Regentis uses Form 6-K to furnish press releases and other information that it makes public in its home market or files with other regulators.
Recent 6-K filings incorporate press releases on clinical and scientific developments for GelrinC, the company’s lead cell-free, off-the-shelf hydrogel implant for focal articular knee cartilage injuries. For example, a 6-K furnishes the press release titled “Regentis’ GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation,” summarizing Phase II data published in the journal Cartilage and describing MRI-based MOCART scores at 24 months. Another 6-K includes the press release “Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC,” outlining patent protection for the liquid, ready-to-use formulation and solvent-free production processes.
Filings also cover corporate and governance events, such as changes in executive leadership, and provide formal notice of these developments under the Exchange Act. In addition, the company’s registration statement on Form F-1 and related documents detail its initial public offering of ordinary shares and listing on the NYSE American under the symbol RGNT.
On Stock Titan, these SEC documents are updated as they are made available through EDGAR. AI-powered tools can help readers quickly understand the key points in each filing, such as clinical endpoints, regulatory milestones, intellectual property disclosures, and changes in management, without needing to parse every page manually.
Regentis Biomaterials filed a Form 6-K to share new long-term MRI data from a completed European clinical trial of its GelrinC® implant for focal knee cartilage defects. Advanced MRI analysis published in the journal Cartilage showed that, by 24 months after treatment, GelrinC®-treated defects were filled with cartilage displaying a layered internal structure similar to healthy hyaline cartilage, which is considered the gold standard for durable joint function.
The imaging was performed using validated methods accepted by the U.S. FDA and EMA and led by Prof. Siegfried Trattnig’s group, recognized experts in cartilage MRI. Regentis states that these findings support the view that GelrinC® promotes true biological cartilage regeneration rather than fibrotic or scar-like repair, reinforcing its ongoing Phase III FDA study and commercialization efforts in Europe, where GelrinC® already has CE Mark approval.
Regentis Biomaterials Ltd. reported a leadership change following the resignation of Chief Executive Officer Dr. Eli Hazum, effective December 31, 2025. The company states that Dr. Hazum resigned for personal reasons and that his decision was not due to any disagreement with the company.
On the same day, the board appointed its Chairman, Dr. Ehud Geller, as the new Chief Executive Officer. This means the roles of Chairman and CEO are now held by the same person, which may influence how the company’s strategy and governance are managed going forward.
Regentis Biomaterials Ltd. filed a Form 6-K as a foreign private issuer with the U.S. Securities and Exchange Commission. The report furnishes a press release dated December 18, 2025, titled “Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC.”
The core update is the disclosure of this new U.S. patent related to GelrinC, which is described as an off-the-shelf regenerative cartilage repair product.
FAQ
What is the current stock price of Regentis Biomaterials (RGNT)?
What is the market cap of Regentis Biomaterials (RGNT)?
